Mohammed S SyedBronx, NY

Mohammed Syed Phones & Addresses

Bronx, NY

Mentions for Mohammed S Syed

Career records & work history

Medicine Doctors

Mohammed Syed

Specialties:
Internal Medicine, Pediatrics
Work:
Flushing Road Internal Medicine & Pediatrics
1201 Flushing Rd STE 1A, Flint, MI 48504
(810) 235-8532 (phone) (810) 235-8203 (fax)
South Saginaw Internal Medicine & Pediatrics
4400 S Saginaw St STE 1315, Flint, MI 48507
(810) 235-8861 (phone) (810) 235-8432 (fax)
Education:
Medical School
Osmania Med Coll, Ntr Univ of Hlth Sci, Hyderabad, Ap, India
Graduated: 1978
Procedures:
Lumbar Puncture, Vaccine Administration, Continuous EKG, Destruction of Benign/Premalignant Skin Lesions, Electrocardiogram (EKG or ECG), Hearing Evaluation, Nutrition Therapy, Pulmonary Function Tests, Wound Care
Conditions:
Abnormal Vaginal Bleeding, Acute Bronchitis, Acute Pharyngitis, Acute Upper Respiratory Tract Infections, Anemia, Attention Deficit Disorder (ADD), Bipolar Disorder, Bronchial Asthma, Candidiasis of Vulva and Vagina, Carpel Tunnel Syndrome, Chronic Bronchitis, Dermatitis, Diabetes Mellitus (DM), Epilepsy, Erectile Dysfunction (ED), Gastritis and Duodenitis, Gastroesophageal Reflux Disease (GERD), Genital HPV, Gout, Hypertension (HTN), Infectious Liver Disease, Intervertebral Disc Degeneration, Iron Deficiency Anemia, Ischemic Heart Disease, Ischemic Stroke, Osteoarthritis, Overweight and Obesity, Peripheral Nerve Disorders, Pulmonary Embolism, Rheumatoid Arthritis, Rotator Cuff Syndrome and Allied Disorders, Sciatica, Substance Abuse and/or Dependency, Venous Embolism and Thrombosis, Vitamin D Deficiency, Abdominal Hernia, Acne, Acute Conjunctivitis, Acute Myocardial Infarction (AMI), Acute Pancreatitis, Acute Renal Failure, Acute Sinusitis, Allergic Rhinitis, Alopecia Areata, Angina Pectoris, Anxiety Phobic Disorders, Aortic Aneurism, Atrial Fibrillation and Atrial Flutter, Bacterial Pneumonia, Benign Prostatic Hypertrophy, Benign Thyroid Diseases, Burns, Calculus of the Urinary System, Candidiasis, Cardiac Arrhythmia, Cardiomyopathy, Cholelethiasis or Cholecystitis, Chronic Renal Disease, Conduction Disorders, Constipation, Contact Dermatitis, Depressive Disorders, Disorders of Lipoid Metabolism, Diverticulitis, Endometriosis, Female Infertility, Fractures, Dislocations, Derangement, and Sprains, Gastrointestinal Hemorrhage, Gingival and Periodontal Diseases, Gonorrhea, Hearing Loss, Heart Failure, Hemolytic Anemia, Hemorrhagic stroke, Hemorrhoids, Herpes Genitalis, Herpes Simplex, Herpes Zoster, Hypothyroidism, Inflammatory Bowel Disease (IBD), Intracranial Injury, Irritable Bowel Syndrome (IBS), Male Infertility, Malignant Neoplasm of Female Breast, Menopausal and Postmenopausal Disorders, Migraine Headache, Mitral Valvular Disease, Multiple Sclerosis (MS), Non-Toxic Goiter, Osteoporosis, Otitis Media, Ovarian Dysfunction, Pelvic Inflammatory Disease (PID), Peptic Ulcer Disease, Plantar Fascitis, Plantar Warts, Pneumonia, Poisoning by Drugs, Meds, or Biological Substances, Polycystic Ovarian Syndrome (PCOS), Post Traumatic Stress Disorder (PTSD), Psoriasis, Sarcoidosis, Schizophrenia, Scoliosis or Kyphoscoliosis, Sexually Transmitted Diseases (STDs), Sickle-Cell Disease, Skin and Subcutaneous Infections, Systemic Lupus Erythematosus, Tension Headache, Tinea Unguium, Transient Cerebral Ischemia, Urinary Incontinence, Urinary Tract Infection (UT), Uterine Leiomyoma, Ventral Hernia, Vitamin B12 Deficiency Anemia
Languages:
English
Description:
Dr. Syed graduated from the Osmania Med Coll, Ntr Univ of Hlth Sci, Hyderabad, Ap, India in 1978. He works in Flint, MI and 1 other location and specializes in Internal Medicine and Pediatrics. Dr. Syed is affiliated with Hurley Medical Center and McLaren-Flint.

Mohammed Syed resumes & CV records

Resumes

Mohammed Syed Photo 36

Mohammed Syed

Mohammed Syed Photo 37

Mohammed Syed

Location:
United States
Mohammed Syed Photo 38

Mohammed Syed

Location:
United States
Mohammed Syed Photo 39

Mohammed Syed - Avenel, NJ

Work:
Jois Construction Management Systems, Inc Sep 2012 to 2000
Senior Project Engineer currently engaged
Management Concept Systems & Services, Inc - Morganville, NJ Jan 2009 to Sep 2012
Sr/Project/ Engineer & Office / Field Engineer
Avila Consultant, LLC - Fairfield, NJ Jun 2008 to Dec 2008
Project Scheduler part-time consultant
Bendheim Wall Systems, Inc - Passaic, NJ Jan 2005 to Dec 2008
Project Cost Engineer
Ellana Inc - New York, NY Jan 2004 to Aug 2004
Assistant Project Estimator & Engineer
Education:
Wayne State University - Detroit, MI Dec 2003
MS in Construction Management
Civil Engineering Osmania University - Hyderabad, Andhra Pradesh Jun 2000
BE
Skills:
Primavera Project Management P6 7.1
Mohammed Syed Photo 40

Mohammed Syed - Queens, NY

Work:
A & Z Pharmaceuticals - New York, NY May 2013 to Jul 2013
Formulation Development Intern
Jawaharlal Nehru Technological University - Hyderabad, Andhra Pradesh 2010 to 2010
Teaching Assistant, Long Island University-Brooklyn Campus, NY
Pharmaceutics International Inc. - Maryland Aug 2013 to Present
Formulation Intern
Education:
Long Island University-Brooklyn Campus, NY
Master of Science in Biochemistry

Publications & IP owners

Wikipedia

Mohammed Syed Photo 41

Sadha

Sadhaf Mohammed Syed (born 17 February 1984), better known as Sadha, is an Indian actress who mainly appears in Telugu, Tamil, Malayalam and Kannada films.

Us Patents

Method And System For Implementing Portal

US Patent:
2007028, Dec 6, 2007
Filed:
Apr 30, 2007
Appl. No.:
11/796918
Inventors:
Ajay Nagpal - Short Hills NJ, US
Ken Umezaki - New York NY, US
Roben Dunkin - Glen Ridge NJ, US
Vinod Vallabhaneni - Hoboken NJ, US
Yuriy Chernyshenko - Staten Island NY, US
Terry Leung - Edison NJ, US
Mohammed Syed - Jersey City NJ, US
Assignee:
Lehman Brothers Inc. - New York NY
International Classification:
G06Q 10/00
G06F 17/18
G06F 3/14
US Classification:
705011000, 715700000
Abstract:
The present invention is directed to a system and method for displaying sales information to a sales person via a portal. Data from a plurality of data sources is aggregated. Sales credit information attributable to the sales person for his clients, and for products associated with one or more of such clients, is identified. Based on (i) user profile information for the sales person, (ii) at least some of the aggregated data, and (iii) at least some of the identified sales credit information, sales strategy information is generated for the sales person. Content of the portal is generated based on the sales strategy information.

Oral Eliglustat Transmucosal Delivery System

US Patent:
2023000, Jan 5, 2023
Filed:
Jul 6, 2022
Appl. No.:
17/811026
Inventors:
- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US
International Classification:
A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/32
A61K 47/36
A61K 47/26
Abstract:
The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

Remdesivir Oral Delivery System

US Patent:
2021037, Dec 9, 2021
Filed:
Jun 7, 2021
Appl. No.:
17/340862
Inventors:
- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Hetalben PRAJAPATI - Dumont NJ, US
Mohammed I. SYED - Dumont NJ, US
Tahseen A. CHOWDHURY - Township Of Washington NJ, US
International Classification:
A61K 31/675
A61K 9/48
A61K 9/00
Abstract:
The present disclosure provides a remdesivir oral delivery system bypassing the first pass hepatic metabolism. More specifically, the disclosure relates to an oral dosage form of remdesivir comprising a lipid based vehicle in an enteric capsule designed to be delivered at intestine to be absorbed by lymphatic pathway, therefore minimizing the first pass hepatic metabolism and improving the oral bioavailability. In some embodiments, the disclosure provides an oral dosage form comprising: (a) remdesivir; (b) a lipid-based vehicle comprising a lipophilic vehicle, an amphiphilic vehicle, a none-aqueous hydrophilic vehicle, or combinations thereof; and (c) an enteric capsule; wherein the remdesivir is dissolved or dispersed in the lipid-based vehicle; and, wherein the remdesivir and the lipid-based vehicle are in the enteric capsule. It also relates to methods of designing and making this dosage form, and methods of usage of this dosage form in the early treatment and prophylaxis of coronavirus infections, e.g., COVID-19.

Oral Eliglustat Transmucosal Delivery System

US Patent:
2019038, Dec 26, 2019
Filed:
Jun 7, 2019
Appl. No.:
16/435071
Inventors:
- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US
International Classification:
A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/26
A61K 47/36
A61K 47/32
Abstract:
The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.